CLASSICAL HODGKIN LYMPHOMA

This study tests a drug called balstilimab in 20 adults with certain lymphomas (classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma) that have returned or not responded to standard treatments. Participants receive the drug every 3 weeks to see if it shrinks tumors a…

This early-stage study tests a new drug called MGD024 in people with certain blood cancers (like leukemia and lymphoma) that came back or didn't get better with standard treatments. The main goal is to find the safest dose and watch for side effects. About 130 adults will receive…

This study tests pembrolizumab, a drug that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to other treatments. The main goal is to see if the drug can shrin…

This study tests a new treatment for children, teens, and young adults (ages 2 to 34) newly diagnosed with classical Hodgkin lymphoma. The drug brentuximab vedotin replaces two older drugs to see if it can shrink tumors faster and more completely, so fewer patients need radiation…

This study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 yea…

This study is testing whether a simple blood test (called a liquid biopsy) can better predict relapse in children and young adults with classical Hodgkin lymphoma. Researchers will track 400 participants under age 25, comparing the test's accuracy to standard PET/CT scans. The go…

This observational study looks at 755 people with classical Hodgkin lymphoma to find better ways to predict if the cancer will come back or resist treatment. Researchers will analyze tumor genetics and PET scan images to identify high-risk patterns. The goal is to personalize tre…